Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform
Linkai Li, Zhongyu Chen, Yunrui Yan, Lening Zhang · 2026
Read Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform by Linkai Li, Zhongyu Chen, Yunrui Yan, Lening Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13189763.txt.
Description
Linkai Li and co-authors review a virus as a tool against lung cancer, in work published in 2026. The virus is vaccinia, long used as a vaccine base. It can infect and kill tumor cells while waking the immune system. That dual action may help where tumors shrug off targeted drugs and immune drugs alike.
The review weighs lab proof on which strains stir immunity best and when gains appear. Design tricks, such as added signaling genes, aim to turn cold tumors hot and pair well with immune drugs. Early patient data look hopeful. Weak delivery through the blood and fast immune pushback stay the chief blocks.
Catalog record
| CREATOR | Linkai Li, Zhongyu Chen, Yunrui Yan, Lening Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 109 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |